KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $235,000.

  • Aquestive Therapeutics' Capital Expenditures rose 193.75% to $235,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $492,000, marking a year-over-year increase of 207.50%. This contributed to the annual value of $159,000 for FY2024, which is 84.02% down from last year.
  • Aquestive Therapeutics' Capital Expenditures amounted to $235,000 in Q3 2025, which was up 119.63% from $107,000 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Capital Expenditures ranged from a high of $826,000 in Q2 2023 and a low of $2,000 during Q1 2023.
  • For the 3-year period, Aquestive Therapeutics' Capital Expenditures averaged around $148,273, with its median value being $80,000 (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first slumped by 98.08% in 2023, then surged by 1,350.00% in 2024.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Capital Expenditures stood at $533,000 in 2021, then slumped by 95.12% to $26,000 in 2022, then plummeted by 38.46% to $16,000 in 2023, then fell by 6.25% to $15,000 in 2024, then surged by 193.75% to $235,000 in 2025.
  • Its Capital Expenditures was $235,000 in Q3 2025, compared to $107,000 in Q2 2025 and $135,000 in Q1 2025.